Compare Adaptive Biotechnologies Corp (ADPT) vs Plby Group Inc (PLBY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Plby Group Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.85 (market cap $3.33B), while Plby Group Inc trades at $1.15 (market cap $136.40M). The key difference: Adaptive Biotechnologies Corp is far larger — about 24.4× Plby Group Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | PLBY | |
|---|---|---|
Market Cap | $3.33B | $136.40M |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $2.71 |
52-Week Low | $10.24 | $1.18 |
Enterprise Value | $3.19B | $284.21M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
PLBY trades at $1.18, down 6.35% today, reflecting ongoing volatility. The stock shows mixed signals with a bearish technical trend but bullish oscillators like RSI at oversold levels. Fundamentally, the company has improved its net loss significantly from -$278M in 2022 to -$13M in 2025, with revenue stabilizing around $121M. Recent news highlights inclusion in Russell indexes and a share repurchase program, signaling management confidence. Cash flow turned positive in 2024-2025 after years of negative operational cash flow, though high debt remains a concern.
The outlook is cautiously optimistic due to improving EBITDA and analyst buy ratings (75%), but risks include persistent net losses, high debt-to-asset ratio near 60%, and competitive pressures in leisure branding. Investment appeal hinges on continued margin improvement and debt management, with current valuation metrics like P/S of 1.05 suggesting potential if execution succeeds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
